Skip to main content

Table 3 Comparison of 11 In-ibritumomab tiuxetan accumulation and intratumoral distribution between responders and non-responders

From: Heterogeneity of intratumoral 111In-ibritumomab tiuxetan and 18F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma

 

Responder ( n= 26)

Non-responder ( n= 16)

p value

SUVmax

2.74 ± 1.43

3.29 ± 1.47

n. s.

% ID/g

0.0022 ± 0.0009

0.0024 ± 0.0008

n. s.

Skewness

0.58 ± 0.16

0.73 ± 0.24

<0.05

Kurtosis

2.39 ± 0.32

2.78 ± 0.53

<0.02

AUC-CSH

0.37 ± 0.04

0.34 ± 0.05

<0.05

  1. n. s., not significant.